Clinical Trial Update: A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification [Phase 1]

View source ↗

Summary

BeiGene is conducting a first-in-human Phase 1 study of BGB-53038, a pan-KRAS inhibitor, as a monotherapy or in combination, in participants with advanced or me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Solid Tumors

Drugs mentioned

• BGB-53038

Snippet

Sponsor: BeiGene | Conditions: Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer | Phase 1 | Status: RECRUITING